Latest News

Chronic hepatitis B affects an estimated 3.2 million people in Europe alone and more than 250 million people globally.

Avlayah’s approval validates Denali’s blood-brain barrier shuttle technology, which the company now applies across five clinical programs targeting Alzheimer’s disease, Parkinson’s disease, and Sanfilippo syndrome type A, among others.

The hospital will roll out in four phases covering technical planning, project management, commissioning, and full operational launch under Apollo’s brand.

The gathering brought together ministers, investors, industry leaders, and development partners to unlock fresh capital for the sector.

The recall covers Citro-Soda Regular in 60g, 120g, and 4g sachet sizes — specifically batches whose numbers begin with the letter “C.”

The initiative directly addresses a fundamental challenge: making scientific careers more attractive while simultaneously creating pathways for professional advancement.

Sha’p Left addresses this directly by positioning its nurse-led surgeries in high-traffic, easily accessible locations such as busy taxi ranks, so that patients can receive care quickly and conveniently.

The drug targets a specific immune deficit associated with bladder cancer, offering a mechanism distinct from conventional treatments.

Gilead will pay USD1.68 billion upfront and commit up to USD500 million in milestone payments to secure gamgertamig (OM336), Ouro’s BCMA/CD3-targeting TCE.

The Global Fund has provided USD 3 million for governance and capacity building, along with USD701 million in programmatic funding.